Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nanjing First Hospital, Nanjing Medical University
The current study is designed as a multicenter, randomized and prospective study aiming to compare the effect of PADN on PAH patients. Based on the previous studies, the rate of pulmonary arterial hypertension (PAH)-related event was around 30% after 6-month treatment using target drugs. And our previous data showed that this PAH-related event at 6-month after PADN procedure was 15%. As a result, a total of 270 PAH patients was required, with 135 patients/per group at a ratio of 1:1 randomization. All patients underwent an 18F-DOPA PET/CT scan of pulmonary arteries and the heart, performed at basement.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Provision of informed consent prior to any study specific procedures;
Men and women 18 years and older;
Group I PAH, defined as a mPAP≥25mmHg, PCWP\<15mmHg and PVR\[The PVR =(mPAP-PCWP)/CO\]\>3.0 Woods unit.
You may not be if
Pregnancy and breast feeding mother;
Estimated life expectancy \<12 months;
Scheduled major surgery in the next 6 months;
Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk;
Previous enrolment in this study or treatment with an investigational drug or device under another study protocol in the past 30 days.